Turkiye Klinikleri Journal of Veterinary Sciences

.: ORIGINAL RESEARCH
Effects of Oleuropein on Nitric Oxide, Glutathione, Malondialdehyde Levels and Glutathione Peroxidase Activities in Various Tissues of Streptozotocin-Induced Diabetic Rats Treated with Metformin and Insulin
Streptozotosin ile Diyabet Oluşturulmuş ve Metformin ile İnsülin Uygulanan Ratlarda Oleuropein'in Çeşitli Dokularda Nitrik Oksit, Glutatyon, Malondialdehit Düzeyleri ve Glutatyon Peroksidaz Aktivitesi Üzerine Etkileri
Nadide Nabil KAMİLOĞLUa, Barış YILDIZa, Oğuz MERHANb, Metin ÖĞÜNb, Aysel GÜVENc, Ekin Emre ERKILIÇd, Tarık MECİTa, Pelin ŞAHİNa, Hülya HASTÜRKa
Departments of
aPhysiology,
bBiochemistry,
dInternal Medicine, Kafkas University Faculty of Veterinary Medicine, Kars, TURKEY
cBaşkent University Vocational School of Health, Ankara, TURKEY
Turkiye Klinikleri J Vet Sci. 2019;10(1):1-10
doi: 10.5336/vetsci.2018-63762
Article Language: EN
Full Text
ABSTRACT
 Objective: The aim of the present study was to investigate the effects of oleuropein on nitric oxide (NO) and oxidant-antioxidant levels in tissues of streptozotocin-induced diabetic rats treated with metformin and insulin. Material and Methods: A total of 40 male Sprague-Dawley rats were used in this study. Animals were divided into 5 groups (n=8) including 3 experiment and 2 control groups. Saline solution was injected intraperitoneally (IP) to the rats in control group. 50 mg/kg STZ was given IP to the Diabetic Control, 50 mg/kg streptozotocin (STZ)+100 mg/kg Metformin+4 IU/kg insulin was given IP to Group 1, 50 mg/kg STZ+100 mg/kg Metformin+4 IU/kg insulin was given IP and 30 mg/kg oleuropein was given orally to Group 2 and 50 mg/kg STZ IP and 30 mg/kg oleuropein was given orally to Group 3. Results: Metformin and insulin with oleuropein have a synergistic effect on regulatory activity of the GSH, MDA, NO levels and GSHPx activities of the kidney, brain and heart tissues. Using metformin and insulin with oleuropein increased the GSH levels of the kidney (p<0.001), brain (p<0.001) and heart tissues (p<0.05); also increased the GSHPx activity of the brain (p<0.01) and the heart tissues (p<0.001) and reduced MDA and NO levels of the kidney, brain and heart tissues (p<0.001). There were no statistically significant differences in GSHPx activity of kidney tissues of experimental groups. Conclusion: Using oleuropein, on streptozotocin-diabetics, in combination with metformin and insulin seems to have synergistic effect on the antioxidants in kidney, brain and heart tissues and effective in regulating the NO level on tissues.

Keywords: Deneysel diabetes mellitus; glutatyon; glutatyon peroksidaz; insulin; malondialdehid; metformin; nitrik oksid; oleuropein
ÖZET
 Amaç: Bu çalışmada, streptozotosin ile diyabet oluşturulmuş ve metformin ve insülin tedavisi gören ratlarda, oleuropein'in dokularda nitrik oksit (NO) ve oksidan-antioksidan düzeyleri üzerine etkilerinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmada, 40 Sprague-Dawley cinsi erkek rat 3 deney ve 2 kontrol olmak üzere, 5 gruba ayrıldı (n=8). Kontrol grubuna intraperitoneal (IP) olarak izotonik sodyum klorür çözeltisi uygulandı. Diyabetik Kontrol Grubu'na IP olarak 50 mg/kg STZ, Grup 1'e IP olarak 50 mg/kg Streptozotosin (STZ)+100 mg/kg Metformin+4 IU/kg insülin, Grup 2'ye IP olarak 50 mg/kg STZ+100 mg/kg Metformin+4 IU/kg insülin ve oral olarak 30 mg/kg oleuropein ve Grup 3'e IP olarak 50 mg/kg STZ ve oral olarak 30 mg/kg oleuropein verildi. Bulgular: Oleuropein ile birlikte metformin ve insülin kullanımının, böbrek, beyin ve kalp dokularının glutatyon (GSH), malondialdehit (MDA) ve NO düzeylerinin ve GSHPx aktivitelerinin düzenlenmesinde sinerjik bir etkiye sahip olduğu belirlendi. Oleuropein ile birlikte metformin ve insülin uygulanmasının böbrek (p<0,001), beyin (p<0,001) ve kalp dokusu (p<0,05) GSH düzeyleri ile beyin (p<0,01) ve kalp dokusu (p<0,001) GSHPx aktivitelerini arttırırken, böbrek, beyin ve kalp dokularında (p<0,001) MDA ve NO seviyelerini azalttığı belirlendi. Grupların, böbrek dokusu glutatyon peroksidaz (GPHPx) aktivitelerinde ise istatistiksel bir farklılığa rastlanmadı. Sonuç: Elde ettiğimiz veriler, streptozotosin ile diyabet oluşturulmuş ratlarda insülin ve metformin ile birlikte oleuropein uygulanmasının böbrek, beyin ve kalp dokularında antioksidan denge ve NO düzeyleri üzerinde düzenleyici aktivite gösterdiğini ortaya koymaktadır.

Anahtar Kelimeler: Experimental diabetes mellitus; glutathione; glutathione peroxidase; insulin; malondialdehyde; metformin; nitric oxide; oleuropein
REFERENCES:
  1. Halifeoğlu İ, Karataş F, Çolak R, Canatan H, Selda T. [Oxidant and antioxidant status in type 2 diabetic patients before and after therapy]. Fırat Tıp Dergisi. 2005;10(3):117-22.
  2. Kakkar R, Mantha SV, Radhi J, Prasad K, Kalra J. Antioxidant defense system in diabetic kidney: a time course study. Life Sci. 1997;60(9):667-79. [Crossref] 
  3. Montes-Cortes DH, Hicks JJ, Ceballos-Reyes GM, Garcia-Sanchez JR, Medina-Navarro R, Olivares-Corichi IM. Chemical and functional changes of human insulin by in vitro incubation with blood from diabetic patients in oxidative stress. Metabolism. 2010;59(7):935-42. [Crossref]  [PubMed] 
  4. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59(7):365-73. [Crossref]  [PubMed] 
  5. Maritim AC, Moore BH, Sanders RA, Watkins JB. Effects of melatonin on oxidative stress in streptozotocin-induced diabetic rats. Int J Toxicol. 1999;18(3):161-6. [Crossref] 
  6. De La Cruz JP, Del Río S, Arrebola MM, López-Villodres JA, Jebrouni N, González-Correa JA. Effect of virgin olive oil plus acetylsalicylic acid on brain slices damage after hypoxia-reoxygenation in rats with type 1-like diabetes mellitus. Neurosci Lett. 2010;471(2):89-93. [Crossref]  [PubMed] 
  7. Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol. 2005;140(2):251-5. [Crossref]  [PubMed] 
  8. Koksal M, Eren MA, Turan MN, Sabuncu T. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J Intern Med. 2011;22(3):249-53. [Crossref]  [PubMed] 
  9. Karabağ-Çoban F, Hazman O, Bozkurt MF, İnce S. Antioxidant status and anti-inflammatory effects of oleuropein in streptozotocin-induced diabetic nephropathy in rats. European J Med Plants. 2017;18(2):1-10. [Crossref] 
  10. Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type ıı diabetes mellitus with and without complications. Clin Sci (Lond). 1996;90(4):255-60. [Crossref]  [PubMed] 
  11. Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr. 2002;76(6):1191-201. [Crossref]  [PubMed] 
  12. Huang PL, Huang PL, Lee-Huang S. Oleuropein and related compounds reduce atherosclerosis. Open Conf Proc J. 2010;1(1):81-6. [Crossref] 
  13. Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga M, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors. 2012;38(6):416-21. [Crossref]  [PubMed] 
  14. Çolak S, Geyikoğlu F, Turkez H, Bakir M, Husseinigouzdaganii M, Can S, et al. The effects of lichens extracts in the healthy rats and the medical utility of these extracts in the prevention of diabetes-associated multiple organ failures. Kafkas Univ Vet Fak Derg. 2015;21(1):101-10.
  15. Visioli F, Poli A, Gall C. Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev. 2002;22(1):65-75. [Crossref]  [PubMed] 
  16. Ogun M, Ozcan A, Karaman M, Merhan O, Ozen H, Kukurt A, et al. Oleuropein ameliorates arsenic induced oxidative stress in mice. J Trace Elem Med Biol. 2016;36:1-6. [Crossref]  [PubMed] 
  17. Gonzalez M, Zarzuelo A, Gamez MJ, Utrilla MP, Jimenez J, Osuna I. Hypoglycemic activity of olive leaf. Planta Med. 1992;58(06):513-5. [Crossref]  [PubMed] 
  18. Al-Azzawie HF, Alhamdani MS. Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. Life Sci. 2006;78(12):1371-7. [Crossref]  [PubMed] 
  19. Cusi K. Metformin: a review of its metabolic effects. Curr Diabetes Rev. 1998;6:89-131.
  20. Correia S, Carvalho C, Santos MS, Proença T, Nunes E, Duarte AI, et al. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem.2008;4(4):358-64. [Crossref]  [PubMed] 
  21. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11(1):1-10. [Crossref]  [PubMed]  [PMC] 
  22. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Thérond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism. 2005;54(6):829-34. [Crossref]  [PubMed] 
  23. Küçükkaya B, Oztürk G, Yalçintepe L. Nitric oxide levels during erythroid differentiation in K562 cell line. Indian J Biochem Biophys. 2006;4(43):251-3.
  24. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5(1):62-71. [Crossref]  [PubMed] 
  25. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43(3):652-71. [Crossref] 
  26. Öztaşan N, Bülbül A, Eryavuz A, Avcı G, Küçükkurt I, Fidan AF. Effect of Yucca schidigera extract on blood pressure, antioxidant activity and some blood parameters in the L-name-induced hypertensive rats. Ankara Üniv Vet Fak Derg. 2008;55: 149-53.
  27. Malinski T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic micro sensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1993;13(3): 355-8. [Crossref]  [PubMed] 
  28. Jiang MH, Kaku T, Hada J, Hayashi Y. 7-nitroindazole reduces nitric oxide concentration in rat hippocampus after transient forebrain ischemia. Eur J Pharmacol. 1999;380(2-3):117-21. [Crossref] 
  29. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882-8.
  30. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun. 1976;71(4):952-8. [Crossref] 
  31. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135(3):372-6. [Crossref] 
  32. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83(2):346-56. [Crossref] 
  33. Singh I, Mok M, Christensen AM, Turner AH, Hawley JA. The effects of polyphenols in olive leaves on platelet function. Nutr Metab Cardiovasc Dis. 2008;18(2):127-32. [Crossref]  [PubMed] 
  34. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25(12):2244-8. [Crossref]  [PubMed] 
  35. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med. 2005;22(4):497-502. [Crossref]  [PubMed] 
  36. Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. Diabet Med. 2002;19(8):685-8. [Crossref]  [PubMed] 
  37. Geyikoglu F, Emir M, Colak S, Koc K, Turkez H, Bakir M, et al. Effect of oleuropein against chemotherapy drug-induced histological changes, oxidative stress, and DNA damages in rat kidney injury. J Food Drug Anal. 2017;25(2):447-59. [Crossref]  [PubMed] 
  38. Mohagheghi F, Bigdeli MR, Rasoulian B, Zeinanloo AA, Khoshbaten A. Dietary virgin olive oil reduces blood brain barrier permeability, brain edema, and brain injury in rats subjected to ischemia-reperfusion. Scientific World Journal. 2010;10:1180-91. [Crossref]  [PubMed]  [PMC] 
  39. González-Correa JA, Mu-oz-Marín J, Arrebola MM, Guerrero A, Narbona F, López-Villodres JA, et al. Dietary virgin olive oil reduces oxidative stress and cellular damage in rat brain slices subjected to hypoxia-reoxygenation. Lipids. 2007;42(10):921-9. [Crossref]  [PubMed] 
  40. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev. 2000;16(6):393-407. [Crossref] 
  41. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-20. [Crossref]  [PubMed] 
  42. Mügge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelial-dependent vascular relaxation in cholesterol-fed rabbits. Circ Res. 1991;69(5):1293-300. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com